Work

Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.4042

Authors: Deirdre Jill Cohen, Jonathan W Lee, Daniel Jacob Becker, Despina Siolas, Nina Beri, Theresa Ryan, Peter Kozuch, Shun Yu, Benjamin A. Levinson, Judith D. Goldberg, Lawrence P. Leichman, Paul Eliezer Oberstein

Institutions: Icahn School of Medicine at Mount Sinai, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, New York University

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4379282661

Cites:

Cited by:

Related to: 10